eli lilly news glp-1 FDA just approved orforglipron (Foundayo), Lilly's oral receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest Eli Lilly's oral GLP-1 pill

The Healthi app makes it easy to stay mindful during this new phase of calmer cravings

JeanGilles explains that understanding how the medication works and what to anticipate helps minimize anxiety and manageable side effects

These supplements contain ingredients that may support your body's natural GLP-1 hormone function and metabolic processes

We provide continuous support, including nutritional counseling and lifestyle recommendations, to complement the medications effects

Providers review chronic conditions, current medications, previous treatments, family history, nutrition, exercise habits, sleep quality, stress levels, and personal treatment goals

This long half-life provides the widest flexibility window for early dosing